Your browser doesn't support javascript.
loading
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Leong, F Joel; Zhao, Rong; Zeng, Shuqi; Magnusson, Baldur; Diagana, Thierry T; Pertel, Peter.
Afiliação
  • Leong FJ; Novartis Institute for Tropical Diseases, Singapore joel.leong@novartis.com.
  • Zhao R; Novartis Institutes for BioMedical Research, Shanghai, People's Republic of China.
  • Zeng S; Novartis Institutes for BioMedical Research, Shanghai, People's Republic of China.
  • Magnusson B; Novartis Pharma AG, Basel, Switzerland.
  • Diagana TT; Novartis Institute for Tropical Diseases, Singapore.
  • Pertel P; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.
Antimicrob Agents Chemother ; 58(11): 6437-43, 2014 Nov.
Article em En | MEDLINE | ID: mdl-25136017
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Piperazinas / Imidazóis / Malária / Antimaláricos Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Piperazinas / Imidazóis / Malária / Antimaláricos Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2014 Tipo de documento: Article